tiprankstipranks
Cardiff Oncology, Inc. (CRDF)
NASDAQ:CRDF

Cardiff Oncology Stock Analysis & Ratings

CRDF Stock Chart & Stats

Day’s Range$1.24 - $1.39
52-Week Range$1.13 - $9.06
Previous Close$1.22
Volume1.09M
Average Volume (3M)812.35K
Market Cap$58.03M
P/E Ratio-1.6
Beta2.03
Next EarningsAug 11, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score7
EPS (TTM)-0.84


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

CRDF FAQ

What was Cardiff Oncology’s price range in the past 12 months?
Cardiff Oncology lowest stock price was $1.13 and its highest was $9.06 in the past 12 months.
    What is Cardiff Oncology’s market cap?
    Cardiff Oncology’s market cap is $58.03M.
      What is Cardiff Oncology’s price target?
      The average price target for Cardiff Oncology is $15.25. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $22.00 ,the lowest forecast is $9.00. The average price target represents 1038.06% Increase from the current price of $1.34.
        What do analysts say about Cardiff Oncology?
        Cardiff Oncology’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Cardiff Oncology’s upcoming earnings report date?
          Cardiff Oncology’s upcoming earnings report date is Aug 11, 2022 which is in 88 days.
            How were Cardiff Oncology’s earnings last quarter?
            Cardiff Oncology released its earnings results on May 05, 2022. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.233 by -$0.017.
              Is Cardiff Oncology overvalued?
              According to Wall Street analysts Cardiff Oncology’s price is currently Undervalued.
                Does Cardiff Oncology pay dividends?
                Cardiff Oncology does not currently pay dividends.
                What is Cardiff Oncology’s EPS estimate?
                Cardiff Oncology’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Cardiff Oncology have?
                Cardiff Oncology has 43,310,000 shares outstanding.
                  What happened to Cardiff Oncology’s price movement after its last earnings report?
                  Cardiff Oncology reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.233. Following the earnings report the stock price went down -1.493%.
                    Which hedge fund is a major shareholder of Cardiff Oncology?
                    Among the largest hedge funds holding Cardiff Oncology’s share is Elkhorn Partners Limited Partnership. It holds Cardiff Oncology’s shares valued at 47K.

                      ---

                      Cardiff Oncology Stock Analysis

                      The Cardiff Oncology stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Cardiff Oncology, Inc.

                      Trovagene, Inc. is a clinical-stage, precision cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      OpGen
                      Quest Diagnostics
                      Enzo Biochem
                      Laboratory

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis